Interview: AbiVax Equipped To Enter Anti-Inflammatory Market
The French biotech's CEO tells Scrip the firm now has the time and resources to sign up a big pharma partner for its ulcerative colitis, RA and Crohn’s candidate.
You may also be interested in...
Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening the blow somewhat of rejection from the US FDA in the biggest market last month.
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.